Toll-like receptors (TLRs) are a family of pattern recognition receptors that play a critical role in the innate immune system's response to pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). In the central nervous system (CNS), TLRs are expressed primarily on microglia, the resident immune cells of the brain, as well as on astrocytes and neurons to a lesser extent. Dysregulation of TLR signaling has been implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). [1]
The TLR signaling pathway represents a critical nexus connecting peripheral inflammation, brain immune responses, and neurodegenerative processes. Growing evidence suggests that chronic TLR activation in the brain contributes to the propagation of neuroinflammation, synaptic dysfunction, and neuronal death characteristic of these disorders. Understanding the specific roles of individual TLRs and their downstream signaling cascades has become a major focus for developing novel therapeutic interventions targeting neuroinflammation. [2]
The mammalian TLR family consists of 10 functional receptors (TLR1-10 in humans), each recognizing distinct ligands: [3]
| TLR | Coreceptor | Ligand/Target | CNS Expression | [4] |
|---|---|---|---|---|
| TLR1 | TLR2 | Triacyl lipopeptides | Microglia > Astrocytes | [5] |
| TLR2 | TLR1/TLR6 | Lipo, peptidoglycan | High in microglia | [6] |
| TLR3 | — | dsRNA | Microglia, neurons | [7] |
| TLR4 | MD-2 | LPS, amyloid-β | Highest in microglia | [8] |
| TLR5 | — | Flagellin | Low expression | [9] |
| TLR6 | TLR2 | Diacyl lipopeptides | Microglia | [10] |
| TLR7 | — | ssRNA, imidazoquinolines | Microglia, neurons | [11] |
| TLR8 | — | ssRNA, imidazoquinolines | Microglia | [12] |
| TLR9 | — | CpG DNA | Microglia, astrocytes | [13] |
| TLR10 | TLR2 | Lipo | Microglia | [14] |
TLR expression varies significantly across cell types in the brain:
Microglia: Express all TLRs at varying levels, with TLR2, TLR4, and TLR9 being most highly expressed. Microglial TLRs serve as the primary sensors for endogenous DAMPs released during neuronal injury or protein aggregation. [15]
Astrocytes: Express TLR2, TLR3, and TLR4 at lower levels than microglia. Astrocytic TLR signaling contributes to the maintenance of the neurovascular unit and can amplify or modulate microglial responses. [@tlr_astrocyte_2024]
Neurons: Express TLR3, TLR7, and TLR8 at lower levels, primarily in specific neuronal populations. Neuronal TLRs may serve defensive functions against viral infections but can also contribute to excitotoxicity when overactivated. [16]
The MyD88-dependent pathway is utilized by all TLRs except TLR3 and is the major signaling cascade for pro-inflammatory cytokine production.
Key steps in MyD88-dependent signaling:
TLR3 and TLR4 can also signal through a MyD88-independent, TRIF-dependent pathway that leads to type I interferon production.
The TLR4-MyD88-NF-κB axis represents the primary pathway for acute neuroinflammation:
Aβ aggregates act as endogenous DAMPs that activate TLR signaling: [5:1]
High mobility group box 1 (HMGB1) is a critical DAMP that synergizes with Aβ to activate TLR4:
The intersection between TLR signaling and NLRP3 inflammasome activation is critical in AD: [13:1]
| Target | Approach | Status | [8:1] |
|---|---|---|---|
| TLR4 antagonists | Eritoran, TAK-242 | Preclinical/Phase I | [2:1] |
| TLR2 antagonists | Anti-TLR2 antibodies | Preclinical | --- |
| MyD88 inhibitors | Small molecule inhibitors | Preclinical | --- |
| HMGB1 antagonists | Anti-HMGB1 antibodies | Preclinical | --- |
| Natural compounds | Curcumin, resveratrol | Preclinical | --- |
α-Synuclein aggregates activate microglia through TLR signaling: [6:1]
Genetic variants in TLR genes modify PD risk: [11:1]
| Gene | Variant | Effect on Risk | Mechanism |
|---|---|---|---|
| TLR2 | R753Q | Altered function | Modified receptor signaling |
| TLR4 | D299G | Increased risk | Enhanced pro-inflammatory response |
| TLR9 | -1237T>C | Modified risk | Altered expression |
TLR signaling in MS involves both protective and pathogenic roles:
Brain aging is associated with dysregulated TLR signaling: [15:1]
Current therapeutic approaches targeting TLRs: [2:2]
| Drug | Target | Phase | Indication |
|---|---|---|---|
| TAK-242 (resatorvid) | TLR4 | Phase I | AD, sepsis |
| Eritoran (E5564) | TLR4 | Phase II | AD |
| OPN-305 | TLR2 | Phase I | ALS |
| IMO-8400 | TLR7/8/9 | Phase I | MS |
| Gene | Variant | Disease | Effect | [17] |
|---|---|---|---|---|
| TLR4 | D299G | AD | Increased risk | --- |
| TLR4 | T399I | PD | Modified risk | --- |
| TLR2 | R753Q | PD | Altered function | --- |
| TLR9 | -1237T>C | ALS | Modified risk | --- |
Chen M, et al. "TLR4 and Alzheimer's disease: from pathogenesis to therapy". Cellular and Molecular Neurobiology. 2023. ↩︎
Gao W, et al. "TLR-targeted therapeutics in neurodegeneration". Pharmacology & Therapeutics. 2024. ↩︎ ↩︎ ↩︎
Kim C, et al. "Toll-like receptor signaling in Parkinson's disease". Journal of Neurochemistry. 2022. ↩︎
Liu Y, et al. "Microglial TLR signaling in ALS". Brain. 2021. ↩︎
Wang Y, et al. "Amyloid-β activates TLR2/TLR4 signaling in microglia". Glia. 2020. ↩︎ ↩︎
Fellner L, et al. "Alpha-synuclein is a endogenous TLR4 ligand". Acta Neuropathologica. 2019. ↩︎ ↩︎
Zhang J, et al. "TLR7/8 activation by TDP-43 in ALS". Nature Neuroscience. 2021. ↩︎ ↩︎
Kagan CL, et al. "Targeting TLRs for neurodegenerative disease treatment". Trends in Pharmacological Sciences. 2023. ↩︎ ↩︎
Lee J, et al. "MyD88 deficiency protects against Aβ pathology". Journal of Alzheimer's Disease. 2019. ↩︎
Park S, et al. "TLR2 deficiency enhances microglial phagocytosis". EMBO Reports. 2020. ↩︎
Miller EC, et al. "TLR4 polymorphisms and Alzheimer's disease risk". Neurology. 2022. ↩︎ ↩︎
Weber MD, et al. "HMGB1-TLR4 axis in neurodegenerative disease". Nature Reviews Neurology. 2023. ↩︎ ↩︎
Zhao Y, et al. "Cross-talk between TLR4 and NLRP3 in neuroinflammation". Cell Death & Disease. 2024. ↩︎ ↩︎
Beyer L, et al. "CSF biomarkers of TLR activation in Alzheimer's disease". Alzheimer's & Dementia. 2024. ↩︎ ↩︎
Hammond TR, et al. "Microglial TLR signaling in brain aging and neurodegeneration". Nature Neuroscience. 2024. ↩︎ ↩︎
Chen X, et al. "Blood-brain barrier modulation by TLR signaling in neurodegeneration". Journal of Cerebral Blood Flow & Metabolism. 2023. ↩︎
Song J, et al. "TLR genetic variants and neurodegenerative disease risk". Neurology Genetics. 2024. ↩︎